AbbVie grew revenue 9 percent to $61.2 billion in fiscal 2025 while Pfizer’s slipped 1.6 percent to $62.6 billion, a split that frames the choice for income investors watching two pharmaceutical giants manage the aftermath of blockbuster patent cliffs.
Revenue paths diverge
AbbVie’s increase came as two immunology drugs generated roughly 42 percent of 2025 sales, offsetting the decline of Humira. Pfizer’s contraction reflects the normalization of its business after the pandemic peak, though Eliquis still contributed about 13 percent of revenue. Net income moved in opposite directions: AbbVie’s fell slightly to $4.2 billion, while Pfizer’s rose substantially to $7.8 billion compared with the result reported two years earlier.
Balance sheets tell different stories
AbbVie ended December 2025 with a debt-to-equity ratio of negative 21.1 times, meaning total liabilities exceeded shareholder equity, and a current ratio of 0.7 times. Free cash flow reached $17.8 billion. Pfizer carried a debt-to-equity ratio of 0.8 times, a current ratio of 1.2 times, and free cash flow of $9.1 billion, enough to fund its dividend and internal research.
Concentration risk on both sides
AbbVie distributes through three major wholesalers, McKesson, Cardinal Health and Cencora, creating customer concentration the company itself flags as a risk. Pfizer’s exposure is tied to a wave of patent expirations across its portfolio and the execution risk of integrating the Seagen acquisition into its oncology pipeline.
Policy and pipeline ahead
The Inflation Reduction Act allows government price setting on several AbbVie products including Botox and Vraylar. Pfizer is deploying pandemic-era capital into obesity and oncology. Both companies face biosimilar competition. The next earnings cycle will show whether AbbVie’s top-line momentum can persist alongside its leverage, and whether Pfizer’s acquisition strategy can arrest the revenue slide.